KIT and gastrointestinal stromal tumor: Imatinib mesylate (IM) is a selective tyrosine kinases inhibitor, including KIT and platelet-derived growth factors (PDGFRs), showing a promising clinical outcome for a patient with an advanced GIST [5] and has been established as the standard first-line therapy [5,6,7,8,9].